<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Ketorolac - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Ketorolac</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Analgesia / Anti-inflammatory</div>
      <h1>Ketorolac</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Ketorolac 10mg Tablets</li>
          <li>Ketorolac 30mg/mL Injection 1mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Moderate to moderately severe pain (short-term use; maximum 5 days total therapy)</strong>
            <ul>
              <li><strong>IM/IV:</strong> 30 mg IV/IM single dose OR 30 mg IV/IM every 6 hours as needed (maximum 120 mg/day)</li>
              <li><strong>PO (if transitioning from parenteral):</strong> 10 mg PO every 4–6 hours as needed (maximum 40 mg/day)</li>
              <li>Combined IV/IM + PO duration: maximum 5 days total</li>
            </ul>
          </li>
          <li><strong>Dose adjustments</strong>
            <ul>
              <li>Adults ≥65 years, renally impaired, or weight &lt;50 kg: reduce dose (e.g., 15 mg IV/IM every 6 hours; max 60 mg/day)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Short-term management of moderate to moderately severe acute pain requiring opioid-level analgesia</li>
          <li>Pain control when oral route not feasible initially (e.g., severe nausea/vomiting, post-trauma)</li>
          <li>Renal colic, musculoskeletal pain, post-procedural pain (selected cases)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>NSAID or ASA hypersensitivity (including ASA-exacerbated respiratory disease)</li>
          <li>Active peptic ulcer disease, recent GI bleeding, inflammatory bowel disease</li>
          <li>Advanced renal impairment or risk of renal failure (dehydration, concurrent nephrotoxins)</li>
          <li>History of or risk for bleeding (anticoagulants, bleeding disorders, perioperative setting with high bleeding risk)</li>
          <li>Cerebrovascular bleeding (suspected or confirmed)</li>
          <li>Pregnancy and labor/delivery (increases bleeding risk; contraindicated in late pregnancy)</li>
          <li>Breastfeeding (excreted in breast milk; avoid)</li>
          <li>Concomitant ASA or other NSAIDs (increases toxicity)</li>
          <li>Use for &gt;5 days increases serious adverse events (GI bleed, renal dysfunction, cardiovascular events)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset, nausea; GI ulceration and bleeding (dose and duration dependent)</li>
          <li>Renal impairment/acute kidney injury (especially with dehydration or pre-existing renal disease)</li>
          <li>Increased bleeding risk (inhibits platelet function)</li>
          <li>Injection site pain (IM)</li>
          <li>Headache, dizziness, drowsiness</li>
          <li>Hypersensitivity reactions (rash, bronchospasm, anaphylaxis in susceptible patients)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>IV:</strong> May give undiluted as slow IV push over ≥15 seconds; flush line before/after</li>
          <li><strong>IM:</strong> Deep IM injection into large muscle (gluteal or deltoid); rotate sites if multiple doses</li>
          <li><strong>PO:</strong> Take with food or milk to reduce GI upset</li>
          <li>Ensure adequate hydration before and during therapy</li>
          <li>Do not exceed 5 days total therapy (combined parenteral + oral)</li>
          <li>Do not co-administer with other NSAIDs or ASA</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Pain relief (assess response within 30–60 minutes IV/IM; reassess need for ongoing therapy)</li>
          <li>Signs of GI bleeding (melena, hematemesis, abdominal pain)</li>
          <li>Renal function monitoring in at-risk patients (dehydration, older adults, pre-existing renal impairment)</li>
          <li>Hydration status (maintain adequate oral/IV fluids)</li>
          <li>Bleeding events (surgical sites, bruising, epistaxis)</li>
          <li>Hypersensitivity reactions (rash, respiratory symptoms)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Reserve for short-term use in moderate-severe pain when other analgesics insufficient; reassess daily</li>
          <li>Document start date clearly and enforce 5-day maximum to prevent serious adverse events</li>
          <li>High risk in dehydration/heat stress environments—ensure hydration and monitor renal risk carefully</li>
          <li>If patient on anticoagulants or antiplatelets, weigh bleeding risk vs benefit; consider alternatives</li>
          <li>Not appropriate for chronic pain or routine mild pain (use acetaminophen/ibuprofen when appropriate)</li>
          <li>If administering IM, ensure proper technique to minimize injection site complications</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (ketorolac tromethamine injection): <a href="https://pdf.hres.ca/dpd_pm/00067838.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067838.PDF</a></li>
          <li>Health Canada product monograph (ketorolac tablets): <a href="https://pdf.hres.ca/dpd_pm/00067839.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067839.PDF</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
